Promising Therapeutics with Natural Bioactive Compounds for Improving Learning and Memory — A Review of Randomized Trials
A recent review has determined that herbal treatments, such as those including flavonoids, are beneficial when attempting to prevent neurocognitive decline, commonly seen in Alzheimer’s Disease. Galantamine, quercetin, examples of two flavonoids, as well as huperzine A, bacoside A, and ginkolide B, three flavonoid-like compounds, all proved to be effective when used as a treatment for poor memory function. The authors mention the need for similar results in clinical trials but find the current data compelling evidence for future drug development.
Highlighted in this paper is the current perception of herbal products as natural, gentle, and safe in comparison to current synthetic drugs. While herbal products are generally safer and considered to be more gentle, it is important to note that for these herbal compounds to truly be effective when treating patients they likely need modification in order to optimize their benefits. The modification would increase potency, selectivity, and pharmacokinetic abilities, as well as lessen any possible side effects. Synthetic drugs may seem frightening, particularly in light of recent illnesses and mortality associated with their abuse, but technology can also be used to optimize novel drugs and it can be efficient to do so.
Cannabidiol: a hope to treat non‑motor symptoms of Parkinson’s Disease Patients
Cannabidiol (CBD) has recently been postulated as an ideal drug to address the treatment of non-motor symptoms of Parkinson’s Disease (PD) due to its multifaceted mechanism of action. The plethora of effects of CBD includes anti-inflammatory, neuroprotective, anxiolytic, and antipsychotic actions, which improve non-motor symptoms of PD and lift the quality of life for patients coping with the illness. Further research is recommended to garner support for FDA approval.
A recently published article serves as a call for research to be conducted to discover how cannabis could impact the management of bipolar disorder (BD). Presented in the article is a full review of the advantages and disadvantages of cannabis-based medicine in the treatment of BD and provides insight into possible mechanisms might affect the pathophysiology of the disorder. The insights listed within the article provide the rationale for examining the endocannabinoid system, specifically the cannabinoid receptor 2, with the hopes of finding therapeutic targets for mood control associated with BD.
A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain ECS
The cannabinoid system provides momentum to develop cannabinoid-based medications to treat inflammatory and neuropathic pain as researchers continue to find promising therapeutic targets. These new targets may lead to the formation of novel pain-relief medications that may serve well to alleviate pain for those suffering from cancer, multiple sclerosis, and fibromyalgia. Cannabis-based pain medicine is also being researched for opioid-sparing effects and effectiveness in reducing the necessary dose of opioids.
Dramatic response to Laetrile and cannabidiol (CBD) oil in a patient with metastatic low grade serous ovarian carcinoma
A recent case study has examined a patient’s response to the consumption of cannabidiol (CBD) as a treatment for a rare type of ovarian cancer. Rather than participate in chemotherapy, which has been shown to only be effective in 5% of patients with low grade serous ovarian carcinoma, an 81-year-old decided to take a combination of amygdalin and CBD. Although CBD has only been shown to have effective anti-cancer properties in murine models the featured patient reported a significant decrease in tumor size, revealing that CBD may, in fact, be an effective treatment for patients looking into alternative care methods.
Although proven ineffective, the use of amygdalin highlights alternative therapies derived from naturally occurring chemicals found in common plants. Flavonoids and terpenes are chemical components of cannabis plants, also found in a variety of fruits and vegetables, that are just now being investigated for their therapeutic benefits. The results of those inquiries may prove useful for similar patients suffering from illnesses that are resistant to the usual treatments.
State laws in Florida allow card-holding seniors to use cannabis, but federally-subsidized senior homes must go against status-quo to allow this. The benefits are not being denied, but if they want to participate in Medicare then cannabis use comes with great risk. http://bit.ly/2LmKJZg
Benjamin Caplan, MDSeniors, in assisted living, and Cannabis
In a crossover trial of 39 patients with Alzheimer’s disease, treatment with nabilone (a synthetic THC analog) was associated with significant improvement in agitation and, remarkably, cognition. Further studies should examine the effects of both THC and CBD in patients with Alzheimer’s disease because anxiety is common in dementia and may exacerbate agitation.
Oxaliplatin is the most commonly used drug to treat colorectal cancer (CRC), but patients often develop resistance to it. So, researchers conducted a study to determine the effect of CBD in overcoming oxaliplatin resistance in CRC cells. They found that elevated NOS3 phosphorylation is an essential part of the development of oxaliplatin resistance, and CBD successfully decreased NOS3 phosphorylation. This effect resulted in cells overcoming oxaliplatin resistance, which suggests that CBD could be a new strategy to treat colorectal cancer.
In the US, the largest increase in cannabis use was seen in the older adult population. And with medical cannabis reducing pain associated with work, researchers wonder if cannabis could postpone retirement plans and enhance the US labor supply. https://www.greenentrepreneur.com/article/335478
Benjamin Caplan, MDThere’s Growing Evidence Cannabis Helps Older Adults Keep Their Jobs for Years Longer